External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology BTOG 2025
Roche and Genentech at

BTOG 2025

March 03 - March 05
Belfast, UK
btog.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
12:00 PM
Duration 90mins Belfast, UK
HORIZON-01: a phase I-III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)
Popat S, Januszewski A, Baijal S, Imseeh G, Gay C, Kerr K, Kato T, Paz-Ares, Zhou C, Redhead K, Theogaraj E, Shagan SM, Solomon BJ
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.